[Clinical outcomes of different regimens for non-Hodgkin's lymphoma with bone marrow involvement: analysis of 148 cases].
OBJECTIVE
To investigate the effects of different treatment protocols on non-Hodgkin's lymphoma (NHL) with bone marrow involvement (BMI).


METHODS
The clinical data of 148 patients of NHL with BMI, 108 undergoing CHOP regimen, 51 undergoing dose-intensive CHOP regimens, 13 undergoing CHOP regimen + rituximab, and 27 undergoing hemopoietic stem cell transplantation (HSCT) after CHOP protocol with remission. The curative effects were retrospectively analyzed.


RESULTS
(1) The response rate (RR) for the whole group was 80.4%, with a complete remission (CR) rate of 60.7%. The response rate of the patients treated with the dose-intensive regimens (dose-intensive group) was 84.3%, significantly higher than that of the patients treated with standard CHOP regimen (64.1%, P < 0.05). (2) The 3- and 5-year overall survival (OS) rates and progress-free survival (PFS) of the B-cell NHL patients who underwent HSCT + Rituximab treatment (Rituximab combined with chemotherapy) were significantly higher than those of the dose-intensive group and CHOP group, and the 3- and 5-year OS rates and PFS of the dose-intensive group were all significantly higher than those of the CHOP group (all P < 0.05). (3) The 3- and 5-year OS rates, and PFS of the T-cell NHL patients who underwent HSCT group and dose-intensive CHOP were all significantly higher than those patients who underwent CHOP regimen (all P < 0.05).


CONCLUSIONS
Superior survival may benefit from Dose-intensive regimens and HSCT, may be good choices for the patients with NHLBMI, a group of heterogeneous malignancies with poor prognosis. And combined chemotherapy with Rituximab treatment remarkably raises the effect for CD20(+) B-cell NHLBMI.
Li
Qiao-Chuan
QC
Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China.
Yuan
Xiao-Li
XL
Wang
Ya-Fei
YF
Zou
De-Hui
DH
Zhao
Yao-Zhong
YZ
Qiu
Lu-Gui
LG
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D001853:Bone Marrow / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003520:Cyclophosphamide; D004317:Doxorubicin; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053208:Kaplan-Meier Estimate; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011241:Prednisone; D016896:Treatment Outcome; D014750:Vincristine; D055815:Young Adult
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone